Price history
Select outcomes to plot.
Description
FDA approves Viatris' low-dose estrogen weekly patch? is a decision window event: the FDA is expected to decide by July 30, 2026, with final resolution by August 13, 2026 at 11:59 PM ET. Approval is defined as issuance of an NDA/BLA approval letter for a new drug, an sNDA/sBLA for a new indication, an ANDA for generics, or a 351(k) for biosimilars. Qualifying approvals include standard or accelerated approvals and REMS or restricted indications; non-qualifying outcomes include CRLs, tentatives, or approvals solely for export/expanded access. Settlement follows the FDA’s official decision or credible reporting consensus if needed.
Event stats
24h volume
Total volume
Liquidity
Markets
1
Market highlights
Top market
24h gainer
24h loser
Highest volume
Top market
24h gainer
24h loser
Highest volume
Related events
Largest IPO by market cap in 2026?SpaceX or OpenAI higher IPO Market Cap?SpaceX Starship fully reusable before 2027?Medline IPO Closing Market CapFDA approves Sanofi’s Subcutaneous Sarclisa?FDA approves AstraZeneca's Truqap (capivasertib)?FDA approves AstraZeneca's Camizestrant?FDA approves Daiichi Sankyo & AstraZeneca's Enhertu?FDA approves Arcalyst technology transfer?SpaceX Starship fully reusable before 2028?
Markets
Outcome | Odds | Spread | 24h Change | 24h Volume | Total Volume | Liquidity | |
|---|---|---|---|---|---|---|---|
| FDA approves Viatris' low-dose estrogen weekly patch? | — | — | — | — | — | — |
Rules
As of market creation, the FDA's expected decision date for the specified application is July 30, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.